A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

Trial Profile

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms PREEMPT-1
  • Sponsors Allergan
  • Most Recent Events

    • 01 Jul 2018 Results of the pooled analysis of PREEMPT 1 and 2 (n=1384) assessing the time of onset of the effect of onabotulinumtoxinA on reduction of headache days and migraine days, presented at the 60th Annual Scientific Meeting of the American Headache Society
    • 10 Jun 2016 Results of pooled analysis of two phase III trials ( PREEEMPT-I and PREEEMPT-II trials) published in the Cephalalgia
    • 31 Aug 2012 Results presented at the 14th World Congress on Pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top